

FOR IMMEDIATE RELEASE



June 6, 2014

AnGes MG, Inc.

**Grant Amount for “2013 Venture Aid Program to Promote Practical Application of Innovation” Confirmed by NEDO  
Regarding Collatogene® (DNA Plasmid with HGF Gene) Lymphedema Project**

AnGes MG, Inc. (“AnGes”) announced that the grant amount has been confirmed for the “2013 Venture Aid Program to Promote Practical Application of Innovation” by the New Energy and Industrial Technology Development Organization (NEDO). As announced by AnGes on May 15, 2014, the Collatogene® lymphedema project was selected for NEDO’s program.

*Project name:* Clinical Development of Lymphedema Treatment Drug using HGF Plasmid

*Grant amount:* 79,808,000 Yen  
(Maximum amount equivalent to two-thirds of actual project costs)

*Period:* May 29, 2014 to February 28, 2015

Details of the program are as announced in the press release “Collatogene® (DNA Plasmid with HGF Gene) Lymphedema Project Selected for NEDO’s Venture Aid Program” on May 15, 2014.

The grant money is expected during the fiscal year ending December 2015, and this will have no effect on the business performance for the fiscal year 2014.

###

*Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.*

<p>AnGesMG, Inc. Corporate Communications TEL:+81-3-5730-2641, FAX:+81-3-5730-2635 <a href="http://www.anges-mg.com">http://www.anges-mg.com</a></p>
--